Latest news
ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote
Peer-reviewed Phase III evERA results show giredestrant plus everolimus substantially extended progression-free survival after CDK4/6 inhibitor treatment in ER-positive, HER2-negative advanced breast cancer, with the strongest effect in ESR1-mutated disease.
IPM Brief – Issue 11 | Medicine Has Left the Building
KRAS Has a New Contender. It Still Has to Earn Its Place.
Migraine Prevention Gets a Wider Door
Stroke Rehab Cannot Stop at Survival
Disaster Shelters Save Lives. Infection Control Cannot Be Improvised.
Cyclospora Is Spreading. The Food Chain Still Has No Answer.
Indigenous cardiovascular inequity is not a data gap. It is a policy failure
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
China’s Biliary-Cancer Bet Has a Global Access Problem
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.